A trial comparing gemcitabine alone with gemcitabine and capecitabine together after surgery to remove cancer of the pancreas (ESPAC-4)

This trial is looking at gemcitabine on its own or alongside another drug called capecitabine after surgery for cancer of the pancreas.

It is open to people with cancer where the pancreatic duct meets the bile duct, the ampulla of Vater. Cancer that starts there is called ampullary cancer.

People who had ductal adenocarcinoma (cancer of the pancreas) were also able to join. But the trial team is no longer recuiting these people.

Cancer Research UK supports this trial.